Imatinib mesylate in the treatment of systemic mastocytosis

@article{Droogendijk2006ImatinibMI,
  title={Imatinib mesylate in the treatment of systemic mastocytosis},
  author={Helga J Droogendijk and Hanneke C. Kluin-Nelemans and Jaap J van Doormaal and Arnold P. Oranje and Arjan A. van de Loosdrecht and Paul L. A. van Daele},
  journal={Cancer},
  year={2006},
  volume={107}
}
Mastocytosis is characterized by the abnormal proliferation of mast cells in 1 or more organs. In most patients, a mutation is present in the gene for C‐KIT, resulting in deregulation of the c‐kit receptor. Imatinib mesylate is a potent inhibitor of c‐kit receptor tyrosine kinase activity. Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis. 
Imatinib mesylate in the treatment of hematologic malignancies
TLDR
The authors review the evidence which led to imatinib approval in the treatment of several of the abovementioned diseases, including systemic mastocytosis and other myeloprolipherative disease-carrying platelet-derived growth factor receptor abnormalities.
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.
  • J. Gotlib
  • Medicine
    Hematology/oncology clinics of North America
  • 2017
TLDR
The understanding of the mutated tyrosine kinome of eosinophilic neoplasms and systemic mast cell disease is discussed, and the successes and limitations of available therapies are highlighted.
Tyrosine Kinase Inhibitors in Systemic Mastocytosis
The strong association of systemic mastocytosis (SM) with mutations and constitutive activation of the receptor tyrosine kinase KIT in >90% of patients has led to great interest in investigating the
Case Report: Treatment of systemic mastocytosis with sunitinib
TLDR
This work presents the first use of sunitinib in systemic mastocytosis, a multi-targeted TKI that has been shown helpful in controlling a murine model of oral allergy syndrome and is presented as a novel treatment for mast cell activation disease.
Mastocytosis: Advances in diagnosis and treatment
TLDR
In vitro experiments showed that mast cells carrying the D816V c-kit mutation were resistant to the prototypical tyrosine kinase inhibitor imatinib, which led to evaluation of small-molecular-weight tyrosINE kinase inhibitors as mast cell cytoreductive agents.
Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant
Mast cell leukaemia (MCL) is a very rare aggressive form of systemic mastocytosis (SM), representing <1% of cases of adult SM in the USA. The diagnosis of MCL requires the presence of SM criteria
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
TLDR
It is confirmed that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D 816v mutation-negative SM.
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
TLDR
The data from these studies indicate that, apart from KIT(D816V), other kinase targets and target pathways may play a role in disease evolution and progression, especially in patients with SM with an associated clonal hematological non-mast cell lineage disease (SM-AHNMD).
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
TLDR
The relevance of the KIT mutational status in selecting SM patients who are candidates for imatinib therapy is supported, including early and sustained CR in four patients, three of whom had extracellular mutations of KIT, and PR in one case.
Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
TLDR
A MCL patient's case with rare phenotypic and genotypic characteristics is described with review of major clinical biological and therapeutic approaches in MCL.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Imatinib for systemic mast-cell disease
TLDR
The results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase in patients with symptomatic systemic mast-cell disease.
Treatment of systemic mast cell disorders.
  • A. Worobec
  • Medicine
    Hematology/oncology clinics of North America
  • 2000
TLDR
Treatment strategies for indolent and aggressive forms of mastocytosis are presented along with a discussion of future therapeutic directions.
Treatment of mastocytosis: pharmacologic basis and current concepts.
TLDR
At the beginning of the new millennium, the therapy of severe forms of aggressive mastocytosis remains a challenge for students of this intriguing disorder.
Response to interferon alfa-2b in a patient with systemic mastocytosis.
TLDR
In systemic mastocytosis, an abnormal proliferation of mast cells infiltrates the skin, bone marrow, spleen, liver, and lymph nodes, and the presence of leukemic circulating mast cells indicates a particularly grave prognosis.
Systemic Mastocytosis
TLDR
The objective of this review is to discuss mastocytosis with a special focus on diagnosis and treatment.
Cladribine therapy for systemic mastocytosis.
TLDR
Single-agent cladribine is an effective and relatively safe treatment for severe systemic mastocytosis, although the optimal dose and schedule need to be explored.
Treatment of systemic mast-cell disease with cladribine.
TLDR
Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers and its therapeutic activity in a patient with interferon alfa–resistant systemic mast-cell disease was evaluated.
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm
TLDR
A mutation is found that results in constitutive activation and expression of c-KIT in mast cells of both skin and spleen, which demonstrates the clonal and neoplastic nature of this form of mastocytosis.
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
TLDR
Observations suggest that the FIP1L1-PDGFRA rearrangement occurs in an early hematopoietic progenitor and suggests that the molecular pathogenesis for a subset of SMCD patients is similar to that of HES.
Clinical scoring of cutaneous mastocytosis.
TLDR
A calculation based on a semi-quantitative analysis of three aspects of mastocytosis was designed, called the scoring index of mastocrytosis (SCORMA), and the clinical use of SCORMA is advocated.
...
1
2
3
4
...